Purpose: The purpose of this study is to attempt to replicate the top single nucleotide polymorphism (SNP) associations from a previous genome-wide association study (GWAS) for the sight threatening complications of diabetic retinopathy in an independent cohort of diabetic subjects from the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR).
Introduction
Diabetic retinopathy is the number one cause of irreversible vision loss in working age adults in the developed world. Over time almost all diabetic individuals will go on to develop diabetic retinopathy 1 . Most of the visual morbidity and attendant health care expense due to diabetic retinopathy can be attributed to its two severe stages: diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR).
There is mounting evidence to support a large genetic contribution to these severe, sight-threatening manifestations of diabetic retinopathy. While epidemiologic studies indicate that the strongest predictors of retinopathy severity correlate with glycemic level and diabetes duration 2, 3 , several recent lines of inquiry now suggest that genetic factors may also predispose and mitigate retinopathy severity. Heritability estimates for the severe manifestations of diabetic retinopathy range from 25% to 50% or more 4, 5 .
While evidence exists that there is a significant genetic component to severe diabetic retinopathy [6] [7] [8] [9] [10] , to date, few genes or pathways have reliably been associated with the development of this disorder. The results of genetic association studies have enjoyed only modest success in identifying genetic variation that may affect risk of retinopathy 11 . These previous studies generally involved modest numbers of cases and controls or trios and have probably been uniformly underpowered to detect genes with modest effect. In addition, many examined only a small number of genes, albeit plausible candidates 12, 13 . Herein, we report a replication analysis of the largest genomewide association study (GWAS) to date for severe diabetic retinopathy.
Methods

Institutional Review Board (IRB) approval
The samples were obtained from all subjects through an approved IRB protocol at the consenting institution. As all patient health information was de-identified prior to genotyping and analysis, the IRB at the University of Chicago declared this study to be non-human subjects research.
Phenotypic Characterization
The present analysis was restricted to Caucasian type 1 diabetic (T1D) subjects, as the previous meta-analysis 11 included only Caucasian T1D subjects. Severe retinopathy cases were identified on the basis of prior laser photocoagulation for either DME or PDR. Details are given below. Controls were all remaining subjects in the cohort. No individuals were excluded on the basis of renal status. Rather, all individuals with the presence of nephropathy, as defined by the presence of end-stage renal disease (ESRD), were removed from a retinopathy-only sub-group analysis. The diagnosis of ESRD was based on a history of kidney transplantation and/or the use of dialysis. Subjects with ESRD were removed to reduce possible confounding given the close correlation between nephropathy and retinopathy and to facilitate assessment for genetic heterogeneity and pleiotropy 14, 15 . (Table 1 )
The GoKinD and EDIC cohorts
Detailed information regarding ascertainment of the Genetics of Kidney in Diabetes (GoKinD) and Epidemiology of Diabetes Intervention and Control Trial (EDIC) cohorts has been previously published 11 (See also Table 2 )
The WESDR cohort
The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) was conducted to assess the prevalence, incidence and progression of diabetic retinopathy and other ocular and systemic complications of diabetes and their relationship to level of glycemia and other risk factors
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. For the study 996 individuals were examined at the baseline evaluation (1980) (1981) (1982) who had insulin-taking diabetes (primarily of type 1) and were less than thirty years of age at the time of diagnosis. Almost all of these individuals were Caucasian (Supplementary Figure 1) . DNA samples for this cohort have been obtained. The WESDR cohort in many ways ideally complements the GoKinD and EDIC samples given its composition of Caucasian T1D subjects followed prospectively with careful phenotypic characterization for renal, ophthalmic, and related endpoints.
Detailed clinical and epidemiologic data were collected on these individuals approximately every 5 years over a 25-year period, including that collected at the fifth follow-up exam (2005) (2006) (2007) . The pertinent parts of the ocular and physical examinations included measuring weight, height, blood pressure, and intraocular pressure; dilating the pupils; taking 30˚ stereoscopic color film fundus photographs of seven standard fields;
performing a semiquantitative determination of glucose, ketone, and protein levels in the urine using Labstix (Ames, Elkhart, IN); and determining blood glucose and glycosylated hemoglobin A1 levels from a capillary blood sample. A structured interview was conducted by the examiners, including questions about specific medications for control of hyperglycemia and blood pressure and use of diuretic agents, the number of aspirin used during the 30 days before the baseline examination, and smoking history. The variables available for selection in all the models for the whole cohort were age, duration of diabetes, gender, glycosylated hemoglobin, change in glycosylated hemoglobin, systolic and diastolic blood pressure, change in systolic and diastolic blood pressure, hypertension, gross proteinuria, and severity of retinopathy at baseline 16, 17 . ). This left 261 who never had signs of PDR or DME at any time. For the purposes of this study, all subjects with either PDR or DME were considered cases. 39.9% of subjects had both PDR and DME. All other subjects in the WESDR cohort, including those with non-proliferative diabetic retinopathy (NPDR) but without DME, were used as controls. In all, there were 208 cases and 261 controls ( Table 2 ). In the sub-analysis, subjects were excluded who had a history of ESRD as defined by prior hemodialysis for renal failure or kidney transplant.
In all, 32 subjects in WESDR were excluded for ESRD, with the remaining cases being used in the sub-analysis.
SNP Selection
Single nucleotide polymorphism (SNP) selection was done using single marker association analyses in typed and untyped (i.e. imputed) SNPs from the GoKinD and EDIC datasets. The follow-up study was designed based on a preliminary analysis prior to imputation of the top associations of the GoKinD-EDIC genome wide meta-analysis 11 .
The 389 SNPs for the follow-up study were selected from three lists comprised of the top preliminary associations from: GoKinD, EDIC, and the combined analysis (Supplementary Table 1 ) and the remainder from the combined analysis (these were selected such that they were different than those in the GoKinD and EDIC lists). For each SNP associated with GoKinD at the level of 2x10 -4 , a region within 50kb on either side of the SNP was defined. SNPs that were associated in EDIC at the 0.05 significance level within this region were selected for replication. The same process was used for EDIC associated regions. Markers showing an r 2 value larger than 0.8 with any other marker in the set were removed from the list.
Genotyping and Quality Control
Genotyping for WESDR subjects was performed on the Illumina™ 1,536-SNP GoldenGate™ custom array. The platform has probe-sets for 1,536 SNPs, and ancestry informative markers were added to the SNP list for an accurate evaluation of population stratification. The genotyping was done at the Center for Inherited Disease Research (CIDR) and the SNP genotypes were called using Illumina software 19 . The number of
SNPs with high quality genotyping scores was 1432. 389 of these SNPs were used for the retinopathy analysis. The remaining SNPs were ancestry informative markers or were used for quality control or to evaluate other phenotypes in WESDR not part of this study, including hypertension, obesity, HbA1c, and nephropathy.
Extensive QC analyses were performed on the WESDR data including detecting relatedness (with three duplicated samples removed), sample contamination, and deviations from the self-reported ethnicity (three samples showing African ancestry were removed, see also Supplementary Figure 1 ). We performed a detailed analysis of the data to untangle any population structure within the samples. The vast majority of the subjects in the WESDR cohort are of individuals reporting European ancestry, but we utilized the genotype data to determine incorrect self-reported ancestry. Population stratification was investigated with EIGENSTRAT 20 . EIGENSTRAT was run on the joint
HapMap and subject samples and on the subject samples separately. The analysis yielded the principal components that were used for identifying outliers, which were excluded from subsequent analyses based on ancestry (Supplementary Figure 1) . The total number of samples remaining was 469. SNPs were filtered using call rate (five SNPs with call rates smaller than 95% were removed) and the test for Hardy-Weinberg equilibrium (two SNPs with HWE p<0.001 were removed). The quality control methods used for GoKinD and EDIC have been previously published 11 .
Statistical Analyses
Association testing for severe diabetic retinopathy was conducted by comparing allele frequency between cases and controls using chi-square tests. The allelic association tests were done in two groups: 1) including subjects with ESRD and 2)
excluding subjects with ESRD. The conventionally accepted threshold of 5x10 -8 was used as the correction for multiple testing to allow for all common variants in the genome 21 . For each SNP, in each dataset, an odds ratio (OR) was calculated. The OR preserves the direction of the effect. A normal approximation was then used to calculate the combined analysis p-values. All combined analysis p-values for severe retinopathy are reported in either Table 3 or Supplementary Table 1 .
Results
We analyzed the WESDR cohort for correlations between study variables and the presence of severe retinopathy ( 
Discussion
In this study the top 389 preliminary genetic associations identified in a genome-wide combined analysis for severe diabetic retinopathy in Caucasian, T1D subjects were tested in a separate, independent cohort from the WESDR. Findings were incorporated in a combined analysis of the WESDR, GoKinD, and EDIC cohorts. No associations were at the level of genome-wide significance.
The strongest association for severe diabetic retinopathy generated by this combined analysis was at rs4865047 in CEP135. CEP135 is expressed in the retina and is involved in centriole adhesion and replication. It interacts with SMAD9, which is involved in TGF-β signaling, a pathway that is upregulated in diabetes 23 . Interestingly, rs4865047 is also 50.5 kb downstream of the gene EXOC1 (exocyst complex component 1). The exocyst complex is required for the insulin stimulated transport of Glut4 to the plasma membrane 24 .
rs476141 was the strongest association from our prior meta-analysis of GoKinD and EDIC. There are several reasons that could explain why its significance did not improve with the addition of the WESDR cohort in this study. First, the association between severe diabetic retinopathy and rs476141 could be a false positive or spurious signal. Second, even though all cohorts are composed of Caucasian subjects, the LD structure of subjects could differ between the three groups of patients. Third, when the p-values for each cohort are analyzed, the signal for rs476141 was primarily generated by the EDIC cohort. EDIC by its design was composed of far greater numbers of subjects with minimal to no retinopathy, creating a substantial difference in the control group composition compared to that of the WESDR and GoKinD cohorts. The signal for rs476141 could be driven by this "squeaky-clean" control group.
In the sub-analysis without ESRD subjects, an association was identified with an There is substantial genetic, biologic and functional data supporting a role for neuropeptide Y signaling in diabetic retinopathy [19] [20] [21] [22] A significant advantage of this study design is the comparability between cases and controls between the three cohorts. We have made a very concerted effort to harmonize the retinopathy phenotype and risk factors between the three cohorts. Three separate, large cohorts of Caucasian T1D subjects of northern European ancestry should help to minimize heterogeneity, exposure to environmental differences, and population substructure.
As cases were defined as those individuals who had received treatment for PDR or DME, it is possible that there was a small amount of misclassification, as some individuals may have been graded as having PDR or DME, but did not have treatment.
It is also possible based on the study design that the case-control groups are not distinct using the phenotypic parameters of DME and PDR. If there was a systematic pattern to this misclassification, it would simply blunt the study's ability to identify an associated allele for severe diabetic retinopathy. It would not introduce a false positive association.
A similar blunting of the power of the study may result from the possibility of a difference in underlying pathophysiology of PDR and DME, though this, again, would not create a type I error.
From a clinical perspective the phenotype of diabetic retinopathy and its characteristic ophthalmoscopic appearance are essentially identical regardless of ethnicity and diabetes type. We anticipate that there may be several genetic variants that may transcend both ethnicity as well as diabetes type. The most important genetic variants may be those that are found across populations, which if present would certainly increase confidence in any positive association. Subsequent analysis of ethnically diverse type 2 diabetes cohorts will be required to evaluate candidate genes in depth and their associated common and uncommon variants that may be markers for the retinopathy phenotype in order to substantiate this hypothesis.
The present study represents one of the largest reported association analyses for diabetic retinopathy to date. Effect size for most significant associations of complex diseases to date has been on the order of a genetic relative risk (GRR) of 1.2 26 . In comparison this study had limited power to detect an allele whose GRR is less than 1.5 unless the risk allele was fairly common in the population. A major lesson of the Wellcome Trust Case Control Consortium (WTCCC) is that not only are large scale genetic association studies feasible and that humans may be the best model organism for the study of complex disease, but also that these studies should in the future be performed on an even a larger scale to increase the analytical power of detection of even more genetic variants 27, 28 . A greater number of subjects may also be necessary to further refine the regions associated with diabetic retinopathy than are currently available from these samples. Age and duration is presented in years, with data taken from the final examination.
Gender is expressed as % of female subjects. HbA1c is expressed as a percentage of glycated hemoglobin. All individuals with ESRD had a history of hemodialysis or of kidney transplantation. Data for HbA1c, blood pressure, and BMI is an average of all study visits over the course of the 25 year study. Standard deviation indicated in parenthesis. In case of ESRD, parentheses indicate number of subjects with ESRD. 
